<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="674">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614549</url>
  </required_header>
  <id_info>
    <org_study_id>N01283</org_study_id>
    <nct_id>NCT00614549</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Levetiracetam in Routine Clinical Practice in Czech and Slovak Republics, Hungary, and Romania.</brief_title>
  <official_title>Long-term Evaluation of the Efficacy and Safety of Levetiracetam in Routine Clinical Practice in the Czech and Slovak Republics, Hungary, and Romania - Non-interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Romania: National Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate, over 1 year period, the efficacy and safety of newly prescribed levetiracetam
      as add-on treatment (POS, myoclonoc seizures in JME and PGTCS in IGE) or primary monotherapy
      (partial onset seizures) in adult and paediatric patients within the approved age limits in
      routine clinical practice in Czech and Slovak Republics, Hungary, and Romania.
      Non-interventional study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Retention rate after 6 and 12 months</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure freedom for the last 6 and 12 months</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2569</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <description>Patients treated with Levetiracetam</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinics and hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnoses of partial onset seizures (POS) with or without secondary generalisation or
             Juvenile Myoclonic Epilepsy (JME) or another IGE with PGTCS

          -  newly prescribed levetiracetam as add-on treatment (POS, myoclonic seizures in JME
             and PGTCS in IGE) or monotherapy (partial onset seizures only) in newly diagnosed
             patients. Newly prescribed means inclusion of the patients in whom a decision has
             been made to prescribe LEV and the first dose is just to be prescribed.

          -  age 4 years or above for partial onset seizures, 12 years or above for MS in JME or
             PGTCS in IGE, 16 years or above for monotherapy

          -  patient written informed consent

        Exclusion Criteria:

          -  indications other than those defined in inclusion criteria

          -  history of allergic or anaphylactic reactions to levetiracetam or other pyrrolidone
             derivatives and excipients included
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <removed_countries>
    <country>Slovakia</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 25, 2012</lastchanged_date>
  <firstreceived_date>January 11, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Levetiracetam</keyword>
  <keyword>Keppra</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
